Tesla gains as Musk buys $1 billion in stock; closes well-off highs
Investing.com -- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced positive results from two Phase 3 trials evaluating first-in-class antibody-blockers targeting cat and birch allergies.
The pharmaceutical company reported that both trials successfully met their primary and secondary endpoints.
The combination therapy was well-tolerated with no serious adverse events reported during the studies.
Following these encouraging results, Regeneron plans to advance its allergy pipeline with additional Phase 3 development scheduled to begin in the first half of 2026.
The trials represent progress in Regeneron’s efforts to develop novel treatments for common allergies using antibody-blocking technology, potentially offering new options for allergy sufferers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.